📰 Clinical Trials Program News
Page 2 - Clinical Trials Program News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Trials Program. Real-time updates on events, politics, business and more.
September 6, 2023
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ACACIA-HCM (Assessment Comparing Aficamten to Placebo on Cardiac Endpoints In Adults with Non-Obstructive
August 2, 2023
David Ziegler, MD, PhD, discusses findings from the phase 2 FIREFLY-1 trial of tovorafenib in pediatric patients with low-grade glioma.
July 7, 2023
THURSDAY, July 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday gave full approval to the Alzheimers drug Leqembi, clearing the way for insurance coverage of
July 7, 2023
THURSDAY, July 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday gave full approval to the Alzheimers drug Leqembi, clearing the way for insurance coverage of
January 13, 2023
The US Food and Drug Administration approved a second drug for Alzheimer Disease, Leqembi, despite reports of rare brain bleeds.
January 10, 2023
The U.S. Food and Drug Administration on Friday approved a second drug for Alzheimer disease, Leqembi (lecanemab-irmb), despite reports of rare brain bleeds linked to use of the drug in some patients.
January 7, 2023
FRIDAY, Jan. 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved a second Alzheimers drug, lecanemab, despite reports of rare brain bleeds linked to use
January 7, 2023
FRIDAY, Jan. 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved a second drug for Alzheimer disease, Leqembi (lecanemab-irmb), despite reports of rare brain bleeds
January 7, 2023
FRIDAY, Jan. 6, 2023 (HealthDay News) -- The U.S. Food and Drug Administration on Friday approved a second Alzheimers drug, lecanemab, despite reports of rare brain bleeds linked to use